Inovio Pharmaceuticals, Inc. (INO)
INO Stock Price Chart
Explore Inovio Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze INO price movements and trends.
INO Company Profile
Discover essential business fundamentals and corporate details for Inovio Pharmaceuticals, Inc. (INO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Dec 1998
Employees
134.00
Website
https://www.inovio.comCEO
Jacqueline E. Shea
Description
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
INO Financial Timeline
Browse a chronological timeline of Inovio Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.51.
Earnings released on 12 Aug 2025
EPS came in at -$0.61 surpassing the estimated -$0.63 by +3.17%.
Earnings released on 13 May 2025
EPS came in at -$0.51 surpassing the estimated -$0.74 by +31.08%, while revenue for the quarter reached $65.34K , beating expectations by +553.43%.
Earnings released on 18 Mar 2025
EPS came in at -$0.69 surpassing the estimated -$0.87 by +20.69%, while revenue for the quarter reached $116.99K , beating expectations by +133.99%.
Earnings released on 14 Nov 2024
EPS came in at -$0.89 surpassing the estimated -$1.20 by +25.83%.
Earnings released on 8 Aug 2024
EPS came in at -$1.19 falling short of the estimated -$1.15 by -3.48%, while revenue for the quarter reached $100.76K , missing expectations by -16.03%.
Earnings released on 13 May 2024
EPS came in at -$1.31 falling short of the estimated -$1.08 by -21.30%.
Earnings released on 6 Mar 2024
EPS came in at -$1.12 surpassing the estimated -$1.27 by +11.81%, while revenue for the quarter reached $102.65K , missing expectations by -69.81%.
Stock split effective on 25 Jan 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$1.08 surpassing the estimated -$1.56 by +30.77%, while revenue for the quarter reached $388.45K , beating expectations by +253.13%.
Earnings released on 9 Aug 2023
EPS came in at -$1.56 surpassing the estimated -$1.68 by +7.14%, while revenue for the quarter reached $225.97K , missing expectations by -13.09%.
Earnings released on 10 May 2023
EPS came in at -$1.92 falling short of the estimated -$1.68 by -14.29%, while revenue for the quarter reached $114.94K , missing expectations by -57.43%.
Earnings released on 1 Mar 2023
EPS came in at -$2.52 falling short of the estimated -$1.92 by -31.25%, while revenue for the quarter reached $124.67K , missing expectations by -63.26%.
Earnings released on 8 Nov 2022
EPS came in at -$1.80 surpassing the estimated -$3.48 by +48.28%, while revenue for the quarter reached $9.15M , beating expectations by +1.37K%.
Earnings released on 9 Aug 2022
EPS came in at -$5.52 falling short of the estimated -$3.60 by -53.33%, while revenue for the quarter reached $784.40K , beating expectations by +48.28%.
Earnings released on 10 May 2022
EPS came in at -$4.32 falling short of the estimated -$3.36 by -28.57%, while revenue for the quarter reached $199.07K , missing expectations by -74.25%.
Earnings released on 1 Mar 2022
EPS came in at -$6.00 falling short of the estimated -$3.96 by -51.52%, while revenue for the quarter reached $839.12K , missing expectations by -66.72%.
Earnings released on 9 Nov 2021
EPS came in at -$3.48 surpassing the estimated -$3.96 by +12.12%, while revenue for the quarter reached $291.70K , missing expectations by -69.93%.
Earnings released on 9 Aug 2021
EPS came in at -$4.68 falling short of the estimated -$3.00 by -56.00%, while revenue for the quarter reached $272.82K , missing expectations by -0.06%.
Earnings released on 10 May 2021
EPS came in at -$3.24 falling short of the estimated -$2.16 by -50.00%, while revenue for the quarter reached $371.12K , beating expectations by +21.21%.
Earnings released on 1 Mar 2021
EPS came in at -$1.68 surpassing the estimated -$2.64 by +36.36%, while revenue for the quarter reached $5.58M .
Earnings released on 9 Nov 2020
EPS came in at -$2.64 falling short of the estimated -$2.16 by -22.22%, while revenue for the quarter reached $236.18K , missing expectations by -56.92%.
INO Stock Performance
Access detailed INO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.